Teluride
Teluride entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.
Timeline
Mon, 27 Jul 2026 11:30:00 GMTEikon Therapeutics Announces First Patient Dosed in - GlobeNewswire
Mon, 27 Jul 2026 07:00:00 GMTEikon Therapeutics Doses First Patient in Phase 2/3 TeLuRide-008 Trial of EIK1001 for First-Line Stage 4 NSCLC - Quiver Quantitative
Related explainers
HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.
Connected entities
Phase2 live mentionsTrial2 live mentionsFirst2 live mentionsLine Stage2 live mentionsEikon Therapeutics Announces1 live mentionsFirst Patient Dosed1 live mentionsGlobeNewswire Eikon Therapeutics1 live mentionsAnnounces First Patient1 live mentionsDosed1 live mentionsGlobeNewswire GlobeNewswire1 live mentions
FAQ
What does this page track?
Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Teluride.
Why might this page be noindex?
Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.
Where should readers verify facts?
Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.
Source diversity
2 distinct publisher/source names are currently connected to this entity page.